<span item_type="fundamental" item_id="1fdd446da3c380a0b1ca9d7be90fc1af" counter_id="ST/US/OACCU" env="prod"></span><span item_type="announcement" item_id="498714133545091841" env="prod"></span><p>Revenue: As of FY2024, the actual value is USD 0.</p><p>EPS: As of FY2024, the actual value is USD 0.12.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any operating revenues to date and does not expect to generate operating revenues until it consummates its initial business combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525065546/d888799d10k.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>For the period from June 28, 2024 (inception) through December 31, 2024, the company had a net income of $1,331,707, which consists of a change on overallotment liability of $94,781 and interest earned on cash held in trust account of $1,588,732, offset by operating costs of $351,806.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525065546/d888799d10k.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>As of December 31, 2024, the company had cash of $193,579,022 held in the trust account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525065546/d888799d10k.htm"></span></li><li>Net cash used in operating activities was $89,687 for the period from June 28, 2024 (inception) through December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525065546/d888799d10k.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company completed the initial public offering of 17,500,000 units, at $10.00 per unit, generating proceeds of $175,000,000.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525065546/d888799d10k.htm"></span></li><li>Simultaneously with the closing of the initial public offering, the company consummated the sale of 550,000 private placement units at a price of $10.00 per private placement unit, generating gross proceeds of $5,500,000.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525065546/d888799d10k.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>The company intends to use the funds held in the trust account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, and structure, negotiate, and complete a business combination.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/2029769/000119312525065546/d888799d10k.htm"></span></li></ul>

Oaktree Acquisition Corp III Life Sciences - Unit | 10-K: FY2024 Revenue: USD 0